An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00343226|
Recruitment Status : Completed
First Posted : June 22, 2006
Last Update Posted : August 25, 2010
|Condition or disease||Intervention/treatment||Phase|
|Liver Transplantation||Drug: Basiliximab||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation.|
|Study Start Date :||May 2002|
|Primary Completion Date :||April 2005|
- Renal function (i.e. glomerular filtration rate) at 12 months post-transplantation
- Frequency and severity of rejection episodes before 6 and 12 months post-transplantation
- Frequency of death, graft loss or retransplantation before 6 and 12 months post-transplantation
- Adverse events
- Duration of initial hospitalization and number or hospital re-admissions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00343226